Defining fast-growing melanomas: Reappraisal of epidemiological, clinical, and histological features

Melanoma Research

Volumn 21, Issue 2, 2011, Pages 131-138

  Martorell Calatayud, Antonio ^a   Nagore, Eduardo ^a   Botella Estrada, Rafael ^a   Scherer, Dominique ^b   Requena, Celia ^a   Serra Guilén, Carlos ^a   Llombart, Beatriz ^a   Sanmartin, Onofre ^a   Kumar, Rajiv ^b   Guillén, Carlos ^a  

^a INSTITUTO VALENCIANO DE ONCOLOGÍA   (Spain)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Breslow; fast growing melanoma; growth rate; melanoma; mitotic rate; prognosis; sentinel node; ulceration

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER EPIDEMIOLOGY; CANCER GROWTH; CANCER SIZE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GROWTH RATE; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; MELANOMA; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; SENTINEL LYMPH NODE; SKIN CANCER; SUN EXPOSURE; SUNBURN;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CELL GROWTH PROCESSES; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; RETROSPECTIVE STUDIES; SKIN NEOPLASMS; SPAIN; YOUNG ADULT;

EID: 79952984154     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/CMR.0b013e328342f312     Document Type: Article

References (33)

1. Ackerman AB. No one should die of malignant melanoma. J Am Acad Dermatol 1985;12:115-116.
2. Geller AC, Swetter SM, Brooks K, Demierre MF, Yaroch AL. Screening, early detection, and trends for melanoma: current status (2000-2006) and future directions. J Am Acad Dermatol 2007;57:555-572; quiz 573-556. (Pubitemid 47384936)
3. Brown L, Palmer PH. Melanoma incidence in Tauranga 1980-1989. N Z Med J 1991;104:109-111.
4. Burton RC, Armstrong BK. Recent incidence trends imply a nonmetastasizing form of invasive melanoma. Melanoma Res 1994;4:107-113. (Pubitemid 24182493)
5. Burton RC, Coates MS, Hersey P, Roberts G, Chetty MP, Chen S, et al. An analysis of a melanoma epidemic. Int J Cancer 1993;55:765-770. (Pubitemid 23354891)
6. Clark WH Jr, From L, Bernardino EA, Mihm MC. The histogenesis and biologic behavior of primary human malignant melanomas of the skin. Cancer Res 1969;29:705-727.
7. Demierre MF, Chung C, Miller DR, Geller AC. Early detection of thick melanomas in the United States: beware of the nodular subtype. Arch Dermatol 2005;141:745-750. (Pubitemid 41001075)
8. Hiatt RA, Fireman B. The possible effect of increased surveillance on the incidence of malignant melanoma. Prev Med 1986;15:652-660. (Pubitemid 17197554)
9. Kricker A, Armstrong BK, Parkin DM. Measurement of skin cancer incidence. Health Rep 1993;5:63-66.
10. Lipsker DM, Hedelin G, Heid E, Grosshans EM, Cribier BJ. Striking increase of thin melanomas contrasts with stable incidence of thick melanomas. Arch Dermatol 1999;135:1451-1456.
11. MacKie RM, Bray C, Vestey J, Doherty V, Evans A, Thomson D, et al. Melanoma incidence and mortality in Scotland 1979-2003. Br J Cancer 2007;96:1772-1777. (Pubitemid 46847216)
12. MacLennan R, Green AC, McLeod GR, Martin NG. Increasing incidence of cutaneous melanoma in Queensland, Australia. J Natl Cancer Inst 1992;84:1427-1432.
13. McMullen EA, Kee F, Patterson CC, Gavin AT, Dolan OM. Improved survival for melanoma in Northern Ireland: a comparison of two 5-year periods (1984-1988 and 1994-1998). Br J Dermatol 2004;151:587-593. (Pubitemid 39330882)
14. Weatherhead SC, Lawrence CM. Melanoma screening clinics: are we detecting more melanomas or reassuring the worried well? Br J Dermatol 2006;154:539-541. (Pubitemid 43382665)
15. Azzola MF, Shaw HM, Thompson JF, Soong SJ, Scolyer RA, Watson GF, et al. Tumor mitotic rate is a more powerful prognostic indicator than ulceration in patients with primary cutaneous melanoma: an analysis of 3661 patients from a single center. Cancer 2003;97:1488-1498. (Pubitemid 36297779)
16. Florenes VA, Faye RS, Maelandsmo GM, Nesland JM, Holm R. Levels of cyclin D1 and D3 in malignant melanoma: deregulated cyclin D3 expression is associated with poor clinical outcome in superficial melanoma. Clin Cancer Res 2000;6:3614-3620.
17. Florenes VA, Maelandsmo GM, Kerbel RS, Slingerland JM, Nesland JM, Holm R. Protein expression of the cell-cycle inhibitor p27Kip1 in malignant melanoma: inverse correlation with disease-free survival. Am J Pathol 1998;153:305-312. (Pubitemid 28317534)
18. Grob JJ, Richard MA, Gouvernet J, Avril MF, Delaunay M, Wolkenstein P, et al. The kinetics of the visible growth of a primary melanoma reflects the tumor aggressiveness and is an independent prognostic marker: a prospective study. Int J Cancer 2002;102:34-38.
19. Liu W, Dowling JP, Murray WK, McArthur GA, Thompson JF, Wolfe R, et al. Rate of growth in melanomas: characteristics and associations of rapidly growing melanomas. Arch Dermatol 2006;142:1551-1558. (Pubitemid 44969210)
20. Richard MA, Grob JJ, Avril MF, Delaunay M, Thirion X, Wolkenstein P, et al. Melanoma and tumor thickness: challenges of early diagnosis. Arch Dermatol 1999;135:269-274. (Pubitemid 29159208)
21. Straume O, Sviland L, Akslen LA. Loss of nuclear p16 protein expression correlates with increased tumor cell proliferation (Ki-67) and poor prognosis in patients with vertical growth phase melanoma. Clin Cancer Res 2000;6:1845-1853. (Pubitemid 30305081)
22. Talve LA, Collan YU, Ekfors TO. Nuclear morphometry, immunohistochemical staining with Ki-67 antibody and mitotic index in the assessment of proliferative activity and prognosis of primary malignant melanomas of the skin. J Cutan Pathol 1996;23:335-343. (Pubitemid 26273329)
23. Balch CM, Soong SJ, Gershenwald JE, Thompson JF, Reintgen DS, Cascinelli N, et al. Prognostic factors analysis of 17600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001;19:3622-3634. (Pubitemid 32786275)
24. Nagore E, Oliver V, Botella-Estrada R, Moreno-Picot S, Insa A, Fortea JM. Prognostic factors in localized invasive cutaneous melanoma: high value of mitotic rate, vascular invasion and microscopic satellitosis. Melanoma Res 2005;15:169-177. (Pubitemid 40839464)
25. Ostmeier H, Fuchs B, Otto F, Mawick R, Lippold A, Krieg V, et al. Prognostic immunohistochemical markers of primary human melanomas. Br J Dermatol 2001;145:203-209. (Pubitemid 32955343)
26. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009;27:6199-6206.
27. Tejera-Vaquerizo A, Barrera-Vigo MV, Lopez-Navarro N, Herrera-Ceballos E. Growth rate as a prognostic factor in localized invasive cutaneous melanoma. J Eur Acad Dermatol Venereol 2010;24:147-154.
28. Nagore E, Botella-Estrada R, Garcia-Casado Z, Requena C, Serra-Guillen C, Llombart B, et al. Comparison between familial and sporadic cutaneous melanoma in Valencia, Spain. J Eur Acad Dermatol Venereol 2008;22:931-936.
29. Nagore E, Botella-Estrada R, Requena C, Serra-Guillen C, Martorell A, Hueso L, et al. Clinical and epidemiologic profile of melanoma patients according to sun exposure of the tumor site. Acta Dermosifiliogr 2009;100:205-211.
30. Nagore E, Pereda C, Botella-Estrada R, Requena C, Guillen C. Acral lentiginous melanoma presents distinct clinical profile with high cancer susceptibility. Cancer Causes Control 2009;20:115-119.
31. Scherer D, Nagore E, Bermejo JL, Figl A, Botella-Estrada R, Thirumaran RK, et al. Melanocortin receptor 1 variants and melanoma risk: a study of 2 European populations. Int J Cancer 2009;125:1868-1875.
32. Vereecken P, Laporte M, Heenen M. Significance of cell kinetic parameters in the prognosis of malignant melanoma: a review. J Cutan Pathol 2007;34:139-145. (Pubitemid 46145553)
33. Friedman RJ, Rigel DS, Kopf AW, Grin CM, Heilman E, Bart RS, et al. Volume of malignant melanoma is superior to thickness as a prognostic indicator: preliminary observation. Dermatol Clin 1991;9:643-648.